Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology.
In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers.
PET Clin. 2015 Jul;10(3):361-74. doi: 10.1016/j.cpet.2015.03.002. Epub 2015 Apr 24.
Bouchelouche K1, Choyke PL2.
1 Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, Aarhus DK-8200, Denmark.
2 Molecular Imaging Program, Building 10, Room B3B6B9F, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.